Business
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Proceeding - Phase 1b Proof-of-Concept
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today\n - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Proceeding\n - Phase 1b Proof-of-Concept Trial Evaluating VK0214 in X-ALD Patients Underway\n - Data From New Program Evaluating Novel Dual Agonists for Metabolic Disorders Presented at ObesityWeek® 2021\n - Balance Sheet Remains Strong, Supporting Advancement of Clinical Programs into Late-Stage Development\n\n\nSAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.\n\n \n \n \n \n \n \n\n \nHighlights from the Quarter Ended September 30, 2021 and Other Recent Events:\n\"The third quarter was a busy and productive time for Viking as we continued to make progress with our lead clinical programs targeting NASH and X-ALD, and expanded our pipeline with an additional program for metabolic disorders,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"Enrollment continues in our Phase 2b VOYAGE trial evaluating VK2809, our novel thyroid hormone beta receptor agonist, in patients with NASH and fibrosis. During the quarter, we also continued enrollment in our Phase 1b clinical trial evaluating VK0214, our second thyroid hormone beta receptor agonist, in patients with X-ALD. VK0214 has demonstrated a promising therapeutic profile in preclinical and clinical studies to date. In addition to our clinical activities, earlier this week we presented two posters at ObesityWeek®, the annual meeting of The Obesity Society, highlighting promising initial data from a series of novel, internally developed dual agonists of the GLP-1 and GIP receptors. These compounds produced significant improvements in metabolic profile in an in vivo model of NASH and obesity, and we expect to begin clinical development with this program in the coming months. Finally, supporting our development activities is a strong balance sheet that has positioned the company well to advance our clinical programs into late-stage development.\"\nPipeline and Corporate Highlights\nPhase 2b VOYAGE study evalua...